Skip to content
Menu
About CLTI
Technology
Products
Clinical Evidence
PROMISE I Study Results
ALPS Post-Market Study
First-in-Human Study Results
Publications
U.S. Clinical Trial
Company
Management
Clinical Advisors
News
Media
Articles
Careers
Contact
International
June
6
2017
LimFlow Expands Senior Management Team and Opens Silicon Valley Office
View the article.
LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia
Related Posts
News
LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS
News
LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT
News
LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING